Generated July 15, 2026 at 8:32 PM ET
· Covers July 15 trading day
· 10 of 154 ready 8-Ks selected
· AI-assisted overview
The day's filings featured two major completed mergers: GSK acquired Nuvalent for $10.6 billion, and Glucotrack completed a reverse merger with Lokahi. Several companies faced negative regulatory or financial events: SPAR Group received a Nasdaq delisting notice, Lipella Pharmaceuticals filed Chapter 11 and sold its assets, and BayFirst Financial restated prior results due to loan adjustments. On the positive side, Axsome Therapeutics received FDA acceptance of its NDA for AXS-12, and Cadiz obtained a BLM right-of-way grant for a water pipeline. Additionally, TriCo Bancshares agreed to be acquired by First Hawaiian, Regen BioPharma settled claims via a dilutive share issuance, and Ensysce Biosciences reported the resignation of its COO.
ENSC
Ensysce Biosciences, Inc.
leadership
negative
materiality 0.60
July 15, 2026, 4:15 PM ET
Ensysce Biosciences COO Jeffrey Millard resigns effective July 10, 2026
- Jeffrey Millard resigned as Chief Operating Officer on July 10, 2026.
- Resignation notice received and effective on the same date.
- No replacement or interim COO has been announced.
regulatory
negative
materiality 0.90
July 15, 2026, 4:39 PM ET
Nasdaq to delist SPAR Group on July 23 after failed reverse split vote
- Nasdaq determined SPAR failed to regain compliance with $1.00 bid price rule by July 13, 2026.
- Company also fails to meet $2.5M minimum stockholders' equity requirement for continued listing.
- Delisting effective July 23, 2026 unless appeal requested by July 21, 2026.
AXSM
Axsome Therapeutics, Inc.
regulatory
positive
materiality 0.80
July 15, 2026, 7:05 AM ET
FDA accepts Axsome's NDA for AXS-12 (reboxetine) for cataplexy in narcolepsy; PDUFA May 1, 2027
- FDA accepted for filing Axsome's New Drug Application for AXS-12 (reboxetine) to treat cataplexy in narcolepsy.
- PDUFA target action date set for May 1, 2027.
- FDA indicated it does not currently plan to hold an advisory committee meeting for the application.
M&A
neutral
materiality 1.00
July 15, 2026, 5:20 PM ET
Glucotrack completes reverse merger with Lokahi; existing holders get 10% floor
- Lokahi shareholders receive 90% of fully diluted equity; existing Glucotrack holders get at least 10%.
- CEO Paul Goode resigns; Erik Emerson appointed CEO and board member effective July 14, 2026.
- Bridge financing of $4.45M via senior secured convertible notes and warrants closed same day.
M&A
neutral
materiality 1.00
July 15, 2026, 9:03 AM ET
GSK completes $10.6B acquisition of Nuvalent; tender offer accepted, merger effective July 15, 2026
- Tender offer closed with 91.3% of shares tendered; all validly tendered shares accepted at $124.00 per share.
- Merger completed under DGCL Section 251(h); Nuvalent becomes wholly owned subsidiary of GSK.
- Total equity value approximately $10.6 billion; funded from GSK credit facilities.
regulatory
positive
materiality 0.75
July 15, 2026, 9:00 AM ET
Cadiz receives BLM right-of-way grant for Northern Pipeline water conversion
- Grant effective July 14, 2026; $2.5M performance bond posted to satisfy remaining conditions.
- Pipeline capacity of 25,000 acre-feet per year; contracts for 85% (21,275 acre-feet) with Inland SoCal water providers.
- BLM completed NEPA Environmental Assessment, issued FONSI, and complied with NHPA and ESA.
litigation
negative
materiality 0.80
July 15, 2026, 4:18 PM ET
Regen Biopharma settles $398,740 claims via share issuance; creates Series N preferred with 75M votes per share
- Court approved settlement with Trillium Partners: Regen will issue shares (common or Series A preferred) to satisfy $398,740 in claims; shares sold by plaintiff, 65% of net proceeds to plaintiff.
- Potential dilution: number of shares indeterminable; as of April 17, 2026, common shares outstanding ~402.9M; CEO David Koos is a creditor and will be paid after one year.
- Created Series N Preferred Stock: 1,000 shares authorized, each with 75 million votes, enabling concentrated voting control.
M&A
neutral
materiality 0.90
July 15, 2026, 4:16 PM ET
TriCo Bancshares to be acquired by First Hawaiian in stock-for-stock merger at 2.095x exchange ratio
- TriCo shareholders to receive 2.095 shares of FHI common stock per TriCo share; fractional shares paid in cash.
- Termination fee of $80 million payable by either party under specified circumstances.
- TriCo CEO Richard P. Smith granted $2.5 million special transaction bonus, payable at closing in cash or restricted stock units.
LIPO
LIPELLA PHARMACEUTICALS INC.
other material
negative
materiality 0.90
July 15, 2026, 10:38 AM ET
Lipella Pharmaceuticals files Chapter 11, sells substantially all assets to XRAIY LLC
- Filed Chapter 11 on March 30, 2026 in Western District of Pennsylvania.
- Entered Asset Purchase Agreement with XRAIY LLC on May 14, 2026 to sell substantially all assets.
- Bankruptcy Court approved sale on June 4, 2026 via Sale Order.
BAFN
BayFirst Financial Corp.
other material
negative
materiality 0.85
July 15, 2026, 4:00 PM ET
BayFirst restates 2024-2026 results; $37M loan adjustments, non-reliance on prior financials
- Asset resolution plan triggers $37.0M in loan adjustments on SBA 7(a) and government-guaranteed portfolios.
- Impairment of $1.5M on non-marketable equity investment and $1.6M write-down on USDA loan premiums.
- 2024 net income restated from $12.6M to $11.4M; 2025 net loss from $22.9M to $24.2M; Q1 2026 net loss from $5.7M to $5.9M.